Targeted therapies in colorectal cancer-an integrative view by PPPM.
Targeted therapies in colorectal cancer-an integrative view by PPPM.
复制标题
DOI：
10.1186/1878-5085-4-3
复制
发表时间：
2013-01-28
期刊：
影响因子：
--
通讯作者：
Doyle B
中科院分区：
文献类型：
--
作者：
Hagan S;Orr MC;Doyle B
在发达国家，结直肠癌（CRC）是第三大最常见的恶性肿瘤，但它是癌症相关死亡的第二大常见原因。临床医生在治疗这种疾病方面仍然面临着许多挑战，未来针对这种疾病的分子特征的方法对这种疾病的成功至关重要。对许多实体肿瘤的遗传分析表明，多达100个蛋白质编码基因发生了突变。在结直肠癌中，已经在许多途径中发现了许多遗传改变。因此，了解结直肠癌的分子病理可能提供潜在治疗途径的信息，也可能提供有价值的预后信息。这将特别适用于分子靶向治疗，如抗血管内皮生长因子治疗和抗表皮生长因子受体（EGFR）单克隆抗体治疗。KRAS和BRAF突变已被证明可以预测抗egfr治疗的反应。由于EGFR也可以通过磷脂酰肌醇3-激酶（PI3K）激酶途径发出信号，因此该途径成员（如PI3K和PTEN）在预测治疗反应中的潜在作用引起了相当大的兴趣。因此，结合新技术，识别这些生物标志物，并结合跨学科方法治疗晚期结直肠癌，将有助于治疗决策过程，也可能指导未来的治疗方法。
In developed countries, colorectal cancer (CRC) is the third most common malignancy, but it is the second most frequent cause of cancer-related death. Clinicians are still faced with numerous challenges in the treatment of this disease, and future approaches which target the molecular features of the disorder will be critical for success in this disease setting. Genetic analyses of many solid tumours have shown that up to 100 protein-encoding genes are mutated. Within CRC, numerous genetic alterations have been identified in a number of pathways. Therefore, understanding the molecular pathology of CRC may present information on potential routes for treatment and may also provide valuable prognostic information. This will be particularly pertinent for molecularly targeted treatments, such as anti-vascular endothelial growth factor therapies and anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy. KRAS and BRAF mutations have been shown to predict response to anti-EGFR therapy. As EGFR can also signal via the phosphatidylinositol 3-kinase (PI3K) kinase pathway, there is considerable interest in the potential roles of members of this pathway (such as PI3K and PTEN) in predicting treatment response. Therefore, a combined approach of new techniques that allow identification of these biomarkers alongside interdisciplinary approaches to the treatment of advanced CRC will aid in the treatment decision-making process and may also serve to guide future therapeutic approaches.